The ability to rapidly identify small molecules that interact with RNA would have significant clinical and research applications. Low-molecular-weight molecules that bind to RNA have the potential to be used as drugs. Therefore, technologies facilitating the rapid and reliable identification of such activities become increasingly important. We have applied a fluorescence-based assay to screen for modulators of hammerhead ribozyme (HHR) catalysis from a small library of antibiotic compounds. Several unknown potent inhibitors of the hammerhead cleavage reaction were identified and further characterized. Tuberactinomycin A, for which positive cooperativity of inhibition in vitro was found, also reduced ribozyme cleavage in vivo. The assay is applicable to the screening of mixtures of compounds, as inhibitory activities were detected within a collection of 2,000 extracts from different actinomycete strains. This approach allows the rapid, reliable, and convenient identification and characterization of ribozyme modulators leading to insights difficult to obtain by classical methodology.
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Much like proteins, RNA molecules can fold into complex threedimensional structures, allowing them to form surfaces and binding pockets to specifically interact with other molecules. RNA performs highly precise functions in a number of essential cellular processes, such as protein synthesis, transfer RNA (tRNA) maturation, and messenger RNA (mRNA) splicing. Furthermore, it has been found that certain structural elements in the mRNA of the human immunodeficiency virus (HIV), namely the trans-activating region (TAR) and the Rev response element (RRE), are critical for retroviral replication 1 . These findings, together with the inability thus far to identify any natural RNA repair mechanisms, make functional RNA molecules attractive drug targets in pharmaceutical research programs [2] [3] [4] . Indeed, antibiotics targeting distinct sites in ribosomal RNA (rRNA) have been known for a long time and are used in clinical practice to fight bacterial infections. For example, aminoglycosides of the 2-deoxystreptamine family specifically interfere with prokaryotic translation by binding to the decoding site of the 16S rRNA (ref. 5) or inhibit virus production by interacting with the RRE and TAR sequences in HIV [6] [7] [8] . Furthermore, small-molecule drugs can influence the cleavage activity of natural ribozymes [9] [10] [11] [12] [13] [14] [15] . It has been suggested that the HHR could be used as a model system for the analysis of RNA/small-molecule interactions, in that it belongs to the most exhaustively characterized catalytic RNAs (refs 2, 4, 14, 16-19) .
Besides rRNA (refs 5, 20) , there have been efforts to target catalytic RNAs in viruses 21 and pathogenic microorganisms with lowmolecular-weight molecules 2, 17 . This seems particularly attractive in that autocatalytic splicing processes and ribozymatic activities involved in virus replication are species-specific, play key roles in the life cycle of microorganisms or viruses, and do not occur in higher eukaryotic cells. For that reason, catalytic RNA is increasingly being considered as a promising drug target 2, 17 . On the other hand, the ability to identify compounds that modulate RNA activity in highthroughput screens is important not only to target biologically active RNA molecules, but also to be able to overcome the growing problem of the global dissemination of bacterial resistance to many of the current antibiotics [22] [23] [24] . These considerations prompted us to design approaches enabling the rapid and convenient identification and characterization of new inhibitors of the HHR, and, ultimately, other functionally interesting RNA molecules. Recently, we have described an assay that enables the rapid kinetic analysis of HHRs by fluorescence resonance energy transfer (FRET) 25 . In contrast to conventional methods, the assay is eminently suited for the high-throughput analysis of ribozyme cleavage activities because it allows the nonradioactive and automated characterization of many RNA-catalyzed reactions in microtiter plates (Fig. 1A,B) . Here we report the rapid identification and characterization of new HHR inhibitors from two small compound libraries using this approach. One library was a collection of antibiotics from which a modulatory effect on RNA molecules could be assumed on the basis of previous data; the other was a collection of extracts from 2,000 different actinomycete strains.
Results and discussion
Inhibitor screening. We have applied a fluorescence-based assay to test 96 antibiotics as well as 2,000 bacterial extracts from actinoRapid identification and characterization of hammerhead-ribozyme inhibitors using fluorescence-based technology
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mycetes with potential antibiotic activity for their ability to modulate the cleavage activity of an in-trans hammerhead ribozyme HHR1 (Fig. 1A) . The kinetic parameters of HHR1 were determined previously under similar conditions under which the screening was performed 25 . In the assay, a fluorophore-labeled oligonucleotide ("FRET-oligonucleotide") serves as a substrate for the hammerhead ribozyme. Upon cleavage of the FRET-substrate, a fluorescence signal proportional to the cleavage activity of HHR1 is generated. By fluorescence monitoring in the linear phase of the reaction, the initial ribozyme-catalyzed cleavage rate could be followed and quantified in subsequent analyses (Fig. 1B) . Recently, the principal applicability of our assay for the kinetic characterization of RNA cleavage reactions was confirmed for other HHRs (ref. 26) . The inhibitor screening was performed in 96-well plates using a fluorescence kinetic reader. The prototype of this assay, that is, automated measurements with manual pipetting, can be applied to record and analyze at least 480 different hammerhead reactions per day. All reactions were performed under multiple-turnover conditions at subsaturating ribozyme concentrations and with substrate in excess. Hammerhead cleavage was initiated by simultaneously adding MgCl 2 and the sample to be analyzed to a preincubated mixture of the ribozyme and the FRET substrate. Kinetics were measured in the initial linear phase of the reaction to ensure that the substrate concentration was not rate limiting. In principle, inhibition was detected by the lower increase of the fluorescence signal relative to the noninhibited HHR reaction.
To improve the accuracy of our assay, a control sample containing no HHR was measured on the same plate for each cleavage reaction (control sample = FRET substrate, compound to be tested, no HHR). The fluorescence signal of the control remained unchanged during the time of the measurement (data not shown), although in some rare cases an increase or decrease of the control fluorescence was observed over time (Fig. 1C,D) . Here, subtraction of the fluorescence signal in the control allowed correction for possible effects of the compound on the FRET substrate that do not result from ribozyme activity, such as nonspecific fluorescence quenching or enhancement, RNA multimerization, or RNase degradation. For example, in the presence of doxycycline and cyclosporin A (Fig. 1C,D) , cleavage is inhibited as indicated by the smaller corrected values (fluorescence units, Fu/min = 2,689 and 2,636, compared to the corrected slope of the uninhibited reaction. Thus, correction led to significantly lower errors in the determination of initial reaction velocities.
We then screened a library of 96 known antibiotics Table 1 ) that was limited to molecules from which an effect on RNA might be expected on the basis of a large set of previous data 10, 12, 15, 21 . (See Supplementary Table 1 in the Web Extras page of Nature Biotechnology Online.) Indeed, 16 compounds showed an inhibitory effect compared to the uninhibited reaction (relative activity <0.7), and among them eight novel inhibitors of the HHR-cleavage reaction were identified: Adriamycin RDF (doxorubicin), bisbenzimide, chelocardin, diminazene aceturate, gramicidin S, 5-epi-sisomicin, tuberactinomycin A (TubA), and tuberactinomycin B (TubB) ( Table 1 ). In Table 1 and in  Supplementary Table 1 the corrected initial velocities for all compounds are listed as relative values of activity with respect to the noninhibited reaction. By far the strongest inhibition was observed with TubB (K i = 110 nM), which was approximately 350-fold more effective than neomycin B (K i = 38 µM), one of the strongest HHR inhibitors presently known. As a positive control, some known HHR inhibitors [12] [13] [14] , such as neomycin B, gentamicin C, paramomycin, and neamine were tested, and their inhibitory potential was quantitatively confirmed in our assay. Furthermore, every inhibitor identified in the FRET assay was independently confirmed by classical polyacrylamide gel electrophoretic (PAGE) analysis using a radiolabeled substrate (see below).
We also screened filtrates from extracts of 2,000 different actinomycete strains with potential antibiotic activity. Each filtrate represented a fixed volume of cell-free supernatant passaged through an ultrafiltration membrane with a molecular-weight cutoff of 3,000 g/mol. The screening was performed as described for the 96 pure compounds, except that no concentration for the components could be calculated for the mixtures. In comparison to the noninhibited reaction, ∼5% of the extracts reduced the cleavage activity to a value of 0.7 or below under the conditions used (data not shown). This value corresponds to the inhibition obtained with 10 µM neomycin, which was measured on the same plates as a positive control. From those extracts that showed inhibition, 58 samples were rescreened in triplicate measurements with almost the same results. Moreover, inhibition was confirmed independently by PAGE analysis (see below). Fractionation of the most active extracts and analyses of pure compound fractions are underway.
Several controls were performed to exclude the possibility that the inhibition obtained in the FRET-assay was due to unspecific fluorescence effects ( Fig. 2A) . In these control experiments a 5′-32 P-labeled substrate of the same sequence without FRET-labeling was used 25 . Reaction products were separated by denaturing PAGE, and product formation was quantified on a phosphorimager. No statistical differences between the FRET and PAGE analyses were obtained, thereby confirming all inhibitors by two independent analyses (Table 1) . It should be noted, however, that for gramicidin S a significant deviation from the FRET data was obtained when we used the "classical" protocol for HHR-cleavage analysis, that is, removing samples for gel electrophoretic quantification at certain time points from a single reaction. For example, 100 µM gramicidin S exhibited a relative activity of 0.6, whereas in the FRET assay the cleavage was almost completely inhibited. We anticipated that this inconsistency was due to aggregation of substrate and gramicidin S. 
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We therefore modified the protocol for the PAGE analysis by monitoring individual samples for each time point, which could be quantitatively analyzed by PAGE. Indeed, by employing this modification we obtained a relative activity of 0.03, thereby establishing gramicidin S as a very potent inhibitor of hammerhead ribozyme cleavage (data not shown).
Kinetic characterization of new HHR inhibitors.
For compounds exhibiting a strong effect on HHR cleavage, K i values were determined by measuring the initial reaction velocities at increasing inhibitor concentrations. Representative results are shown in Figure  2B ,C and Table 1 . As control, a selection of six more or less inhibitory antibiotics were chosen and remeasured from independently diluted stock solutions (Table 1, Table 1 . Interestingly, curve fitting revealed a positive cooperativity for the inhibition by TubA (Fig. 2C , cooperativity factor: 1.5).
Interestingly, some striking similarities and interesting differences become evident when inhibitors of other ribozymes [27] [28] [29] [30] are compared with our results. For example, among the aminoglycosides, 5-epi-sisomicin was identified as the strongest hammerhead inhibitor, with a K i of 1 µM, followed by gentamicin C complex (10 µM), neomycin sulfate (18 µM), gentamicin C1A sulfate (32 µM), neomycin B (38 µM), paramomycin (65 µM), and neamine (90 µM). 5-epi-Sisomicin and gentamicin also showed strong inhibitory potential for the sunY intron and the HDV ribozyme 21 . Inhibition of the HHR by neomycin is comparable to the HDV ribozyme; inhibition by paramomycin is comparable to the value of K i obtained for the sunY intron.
Whereas the cyclic pentapeptide antibiotics TubA and TubB showed very strong inhibition, other peptide antibiotics of the same family, namely TubN (enviomycin), viomycin, and capreomycin (capastat) were much less effective or had no effect at all. Interestingly, the strongest HHR inhibitors TubA and TubB both contain an OH group in α-position to the guanidino group in the six-membered ring. All noninhibitory tuberactinomycins, except viomycin, lack this functionality. A similar trend is found for the sunY intron and the HDV ribozyme 21 , but here viomycin exhibits moderate inhibitory potential.
The striking difference in inhibitory activity found for viomycin and TubB in our study is remarkable because these two peptide antibiotics are considered to be identical. Our data strongly suggest that the two samples referred to as TubB and viomycin obviously differ in some respect and thus cannot be considered identical. Indeed, the two samples were isolated from different streptomycete strains, and have different counter-ions: "viomycin"·H 2 SO 4 from Streptomyces vinaceus; "TubB"·HCl from Streptomyces griseoverticillus. At present, we do not know whether this may explain differences in the inhibitory potential of viomycin and TubB.
The third class of inhibitors identified in our screen belongs to the tetracycline family. Previously, tetracycline was established as a moderate HHR inhibitor 12 and this was confirmed by our study. Chelocardin exhibited significantly stronger inhibitory potential. No inhibition was detected for oxytetracycline.
For the anthracycline antibiotic Adriamycin (doxorubicin), which belongs to the family of aromatic type II polyketides, a K i of 23 µM was measured. Doxorubicin is known to interact with DNA and was recently shown to bind reversibly to RNA helices and to tRNA 31 .
A novel class of potent hammerhead inhibitors is represented by two dye molecules that have not yet been shown to affect ribozyme catalysis, namely bisbenzimide (Hoechst 33258), and the bis-N-acetylglycine salt of 4,4'-(diazoamino)di-benzamidine (diminazene aceturate), which showed K i values of 3 µM and 20 µM, respectively. To our knowledge, bisbenzimide has not been identified as an inhibitor of ribozyme activity but was recently shown to be a weak inhibitor (>>100 µM) of the Tat/TAR interaction in vitro 32, 33 . Bisbenzimide was also used as a target for an RNA aptamer selection 34 , and the consensus motif 5′-UUAN 4-5 UCU-3′ was identified in the selected sequences. This motif is not present in HHR1. The second dye inhibitor, diminazene aceturate, exhibits a K i of 20 µM. This drug was shown to interact with TAR RNA (ref. 35 ) and an RNA duplex 36 , probably by a combination of intercalation plus minorgroove binding.
Statistical analysis. To ensure the assay's general applicability for the high-throughput screening of large compound libraries, we had to ensure that it can identify inhibitors reliably and accurately. We therefore statistically evaluated two different sets of data that may be utilized for the analysis of a screening experiment: the initial slopes of the fluorescence signal reflecting the cleavage kinetics that were used throughout this study, and the percentage of cleavage at a defined time point after the start of the reaction. To determine which of the two options would lead to highest accuracy, 48 measurements of the uninhibited reaction were analyzed. Figure 3A shows the distribution of the corrected slopes (see Fig. 1C,D) fitted into a Gaussian distribution, from which confidence intervals were inferred. An analogous analysis for the corrected relative fluorescence values obtained after 4 min of measurement is shown in Figure 3B .
The standard deviations for the two analyses show significant differences. For the analysis based on the initial slopes the standard deviation was 7%, compared to 18% for the single-point analysis.
The confidence interval, that is, the value one would expect for The same in-cis snorbozyme construct as described before with a hammerhead sequence (52 nucleotides) inserted into a full-size U3 variant was used 37 . RNA was identified by northern blot as described 37 
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99.99% of all experiments, ranged between 0.73 and 1.27 for the slope-based data. Therefore, the risk of obtaining false positives is one in 10 4 if the threshold for inhibition is set to 0.7 relative to the uninhibited reaction. For the single-point analysis the confidence interval ranged between 0.31 and 1.69. This does not mean that the analysis based on single-point determinations is not useful, especially in cases in which a lower threshold (0.3) is sufficient. For a rapid analysis of large libraries of individual compounds it might be advantageous to choose single-point analysis because it may, for example, allow the screening of a larger number of compounds in a primary screen because of the shorter time intervals required. In conclusion, the statistical evaluation shows that our assay is capable of detecting even very weak inhibitory activities. This is less relevant if individual, defined compounds are screened but may become highly relevant if more or less complex mixtures are searched in a primary screen, as in the case of screening 2,000 different bacterial extracts of mixed composition.
Cleavage of a HHR snorbozyme is reduced by TubA in vivo. To investigate whether some of the identified HHR inhibitors can also act inside cells, we employed the "snorbozyme" methodology, which utilizes U3 small nucleolar RNA-hammerhead ribozyme hybrids to accurately and reliably assay ribozyme activity in vivo 37, 38 . Using the cis-snorbozyme (Fig. 4A) , we evaluated the intracellular inhibition of HHR cleavage by six inhibitors, namely bisbenzimide, TubA, TubB, doxorubicin, diminazene aceturate, and 5-epi-sisomicin in yeast cells. Cells were grown at various permissive concentrations of inhibitors (TubB and bisbenzimide exhibited cell toxicity at 100 µM and 10 µM concentrations, respectively; other compounds were toxic at 1.0 mM), the RNA was isolated at the same growth stages, and snorbozyme substrates and cleavage products were subsequently quantified by northern blotting. TubA was the only compound for which a reduction of HHR cleavage in vivo was observed ( Fig. 4B,C ; data for the remaining inactive compounds not shown). TubA added to the growth medium at 300 µM reduced snorbozyme cleavage in vivo by nearly 30% (compare lanes 2 and 3). Although not dramatic, the effect was clearly concentration-dependent and highly reproducible within three independent experiments. To our knowledge, this is the first example showing that ribozyme-activity can be reduced by a small molecule in vivo.
It is not completely clear why some compounds that are potent inhibitors in vitro do not show activity in vivo. For TubB and bisbenzimine, the explanation can be as simple as that their high toxicity does not allow them to reach the intracellular concentration of the compound necessary for inhibition. For others, such reasons as low permeability of cell membranes and low accessibility of the ribozyme segment as part of the RNP complex might provide an explanation. With ribozymes as in vivo targets, factors such as the mechanism of inhibition may also be important. In this context it is interesting to note that TubA, the only compound active in vivo, showed positive cooperativity of HHR inhibition in vitro with a cooperativity coefficient of 1.5 (Fig. 2) . This effect was not observed with TubB, which points to slight differences in the inhibitory mechanisms that may play some role in vivo.
In summary, we have described a new approach for the rapid and convenient identification of new ribozyme inhibitors from a small, constrained antibiotic library. With a nonautomated, nonoptimized laboratory prototype we could easily analyze at least 480 different ribozyme reactions per day. This approach should be generally applicable for the rapid identification of low-molecular-weight modulators of functional RNAs. These are lead candidates not only for facilitating our understanding of RNA-drug interaction but also for providing valuable information for the rational design of new antibiotic reagents targeting RNA. The approach can also serve as a starting point for the development of high-throughput screening systems directed against a variety of RNA-catalyzed or RNA-modulated cellular processes such as bacterial mRNA splicing. Toward this end, we showed that inhibition of hammerhead ribozyme catalysis was reliably detectable within 2,000 uncharacterized bacterial extracts. In general, low-molecular-weight molecules that bind to RNA have the potential to be used as drugs, which would open up a whole new line of investigation for the pharmaceutical industry.
Experimental protocol
Kinetic measurements. Kinetic parameters of ribozyme cleavage were determined under multiple-turnover conditions with 8 nM HHR1 and 200 nM FRET-substrate SL1 using a Biolumin 960 fluorescence reader (Molecular Dynamics, Sunnyvale, CA). All reactions were carried out in 50 µl final volume in 0.5× PBS with 8.0 mM MgCl 2 at 32°C and pH 7.4. Preceding each measurement, stock solutions of ribozyme and substrate were incubated separately at 85°C (HHR1 for 3.5 min in 1× PBS; SL1 for 1.5 min in water), cooled to 32°C within 15 min, combined and, after 15 min, dispensed on 96-well plates (30 µl/well). Reactions were initiated by adding MgCl 2 and antibiotic simultaneously. Fluorescence was recorded at 14 s intervals. Raw data were exported to Microsoft Excel and analyzed with a program that is available on request. Negative control reactions with an inactive HHR1 mutant 25 . Analyses with 32 P-labeled substrate S1 were done analogously using the standard protocols based on gel electrophoretic separation and phosphorimager quantification.
Inhibition constants (K i ). K i values for antibiotic inhibition of ribozyme cleavage were obtained by measuring the initial reaction velocities at different antibiotic concentrations. For each experiment, a 240× mix of SL1 with and without HHR1 was prepared and transferred into six plates (30 µl/well). Each plate contained four different antibiotics at eight different concentrations, measured in triplicates. For analysis, the relative activity (r a ; see above) was plotted against the inhibitor concentration (c), and K i values were determined by fitting the data points to the equation (1 + c/K i ) -1 using the least square method (TubA was fitted to [1 + (c/K i ) n ] -1 , where n is a cooperativity factor).
In vivo inhibition studies. Yeast cells expressing active cis-snorbozyme (plasmid pRS:T/C(+); see ref. 37 ) were grown overnight in 5 ml of YNB (0.67% yeast nitrogen base) selective medium, containing 2% glucose and indicated amounts of inhibitors. Cells expressing inactive (mutant) cis-snorbozyme (pRS:T/C(-); see ref. 37) were grown in the same medium without inhibitors. In cases where inhibitors turned out to be toxic, reduced cell growth was observed. The RNA was isolated from the surviving cells at approximately the same growth stage (0.8-1.0 OD 600 ), and subjected to northern blotting with the 32 P-labeled oligonucleotide SD13* (5′-GCGGCT-TAGGCTAAGCTAAGGCCAGC-3′), specific to the snorbozyme molecule 37 . Quantification was by phosphorimaging.
